Last mentioned: 3d ago
30-patient milestone announced
BellaSeno reports that 30 women have now been treated (19 from the initial study + 11 in the pivotal trial) and highlights progress toward global market entry.
Two-year outcomes presented at The Aesthetic MEET 2026
Professor Anand Deva presents two-year follow-up data showing no scaffold-related complications and 83% mean breast volume retention.
Pivotal clinical trial launched
BellaSeno starts its pivotal trial in Australia to gather evidence for broader regulatory approval and global commercialization.
Initial study enrollment completes
The 19-patient first-in-human safety cohort is fully enrolled; patients are followed for two years.
First-in-human safety study begins
BellaSeno initiates a 19-patient clinical investigation of its breast scaffolds in Australia, aimed at assessing initial safety and tissue regeneration.
BellaSeno announced two-year follow-up data from its first-in-human breast scaffold trial, showing an 83% mean volume retention and zero scaffold-related complications in 19 patients. An additional 11 patients are enrolled in a pivotal Australian trial, with global commercialization as the next goal.
This page surfaces every story mentioning Professor Owen Ung across our healthcare coverage. We track each entity's appearance over time so readers can trace how the narrative evolves — which developments are isolated incidents, which build into longer arcs, and which reframe how operators in the space think about the entity. Story selection uses the same multi-source verification gate applied across the rest of our coverage.
Read our editorial methodology for how we identify, deduplicate, and score entity references. Our glossary defines the technical terms used across stories on this page, and our trends index contextualizes individual developments against the longer-running healthcare beat. Cross-entity comparisons live on our compare view.
| What you see | What it tells you |
|---|---|
| Story count | Number of distinct stories where Professor Owen Ung was a primary or referenced actor. |
| Recency clustering | Whether mentions are concentrated in a recent window (a news cycle) or distributed (a sustained arc). |
| Sentiment distribution | Aggregate sentiment of the stories mentioning this entity, weighted by impact score. |
| Cross-niche links | When the same entity surfaces in our sibling networks, we link to those views to enrich context. |